drugset / Trial / NCT07089940
OMO-103 for the Treatment of Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma
Phase 0
Recruiting
12 enrolled
OHSU Knight Cancer Institute
Brendon-Colson Center · collabOregon Health and Science University · collabPeptomyc S.L. · collab
NaSingle-groupOpen-labelTreatment
Summary
This early phase I trial studies the biological activity of OMO-103 in patients with pancreatic ductal adenocarcinoma that has spread to nearby tissue or lymph nodes (locally advanced) or that has spread from where it first started (primary site) to other places in the body (metastatic). OMO-103 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. This trial may help researchers determine how exposure to OMO-103 changes pancreatic tumor cells.
Timeline
- Start
- 2026-01-27
- Primary completion
- 2027-12-31
- Completion
- 2027-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | OMO-103 | Protein / enzyme biologic | — | Intravenous |